Latest Conference Articles

A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast cancer trials beyond binary pCR.

With long-term follow-up, HLA-A*02:01–positive patients with metastatic uveal melanoma maintained survival benefit with the bispecific agent vs investigator's choice.

Bayesian modeling links residual cancer burden shifts to survival, helping neoadjuvant breast cancer trials and FDA approvals predict real benefit.

mRNA-4359 demonstrated high response rates and antigen-specific T-cell activation in a small cohort of previously untreated patients.

Dr Bazhenova presents TRUST data at AACR 2026, showing taletrectinib reached a 46.1-month PFS and 89.8% ORR in TKI-naive, ROS1-positive metastatic NSCLC.

A brain-penetrant pan-RAF/MEK molecular glue demonstrated a 38% response rate in a heavily pretreated melanoma population that currently has no approved targeted therapies.

Darlifarnib may enable the rechallenging of patients with cabozantinib in a combination context for patients with clear cell renal cell carcinoma.

Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer patients from the RUBY trial.

Rezatapopt showed clinical activity across subgroups in patients with TP53 Y220C-mutated ovarian cancer in the phase 2 PYNNACLE trial.

At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ovarian cancer.

Bradley Monk, MD, discusses the KEYNOTE-B96 trial in which pembrolizumab plus paclitaxel +/- bevacizumab improved OS in platinum-resistant ovarian cancer.

MSK experts discuss FLAURA2 updates, emerging targets in mesothelioma, and next-gen immunotherapies from the 2026 European Lung Cancer Congress.

Tisotumab vedotin plus carboplatin and pembrolizumab ± bevacizumab elicited antitumor acitivity in a phase 1/2 cervical cancer trial.

HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety profiles per 2026 SGO data.

Roisin E. O'Cearbhaill reviews a phase 1/2 trial evaluating REGN5668, a MUC16×CD28 bispecific antibody, in combination with other targeted therapies for recurrent ovarian and endometrial cancers.

Mirvetuximab soravtansine plus carboplatin showed promise in patients with FRα-positive platinum-sensitive ovarian cancer.

The novel FRα-targeted ADC sofetabart mipitecan showed strong antitumor activity in patients with heavily pretreated platinum-resistant ovarian cancer.

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with HER2-expressing endometrial cancer.

Final ROSELLA overall survival results show adding relacorilant to nab-paclitaxel reduces risk of death by 35% in platinum-resistant ovarian cancer.

Experts from Memorial Sloan Kettering Cancer Center discuss updates from the 2026 European Lung Cancer Congress.

Findings from the PARADIGM trial suggest that the use of azacitidine and venetoclax could replace intensive chemotherapy in younger, fit patients with acute myeloid leukemia.

Dr Nicolas Girard discusses PALOMA-2 at ELCC 2026, highlighting the 85% ORR and safety of subcutaneous amivantamab plus lazertinib in first-line EGFR+ NSCLC.

With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses practice-changing presentations from the 2026 ASCO GU Cancers Symposium.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

The ASTEROID trial shows adding durvalumab to SBRT significantly cuts tumor progression in early-stage NSCLC, though OS and DFS benefits remain uncertain.

Phase 2 interim safety data presented at the EBMT 2026 Annual Meeting suggest no additive toxicity with the novel combination chronic GVHD regimen.

New first-line ES-SCLC data show iza-bren plus serplulimab drives 88% responses and manageable safety, setting up phase 3 trials.

Phase 1 data show that setidegrasib degrades KRAS G12D, delivering durable NSCLC responses with manageable safety and biomarker-linked benefit as phase 3 plans advance.

ABC trial interim results demonstrate effective, short-duration prophylaxis without conventional immunosuppressants and with dose-reduced cyclophosphamide.

Most patients with heavily pretreated chronic GVHD experienced clinical benefit with axatilimab, with the majority continuing treatment after approval.